Insider Selling: CeriBell (NASDAQ:CBLL) CTO Sells 1,966 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 1,966 shares of the company’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $18.00, for a total transaction of $35,388.00. Following the sale, the chief technology officer directly owned 195,682 shares in the company, valued at $3,522,276. This represents a 0.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Raymond Woo also recently made the following trade(s):

• On Friday, May 1st, Raymond Woo sold 11,104 shares of CeriBell stock. The shares were sold at an average price of $20.44, for a total value of $226,965.76.
• On Wednesday, April 1st, Raymond Woo sold 11,112 shares of CeriBell stock. The stock was sold at an average price of $18.56, for a total value of $206,238.72.
• On Monday, March 2nd, Raymond Woo sold 8,087 shares of CeriBell stock. The stock was sold at an average price of $18.25, for a total transaction of $147,587.75.

CeriBell Stock Performance

Shares of CBLL stock traded up $0.03 on Tuesday, hitting $18.80. The company’s stock had a trading volume of 187,155 shares, compared to its average volume of 322,889. CeriBell, Inc. has a fifty-two week low of $10.85 and a fifty-two week high of $24.33. The stock’s 50 day moving average is $19.08 and its 200-day moving average is $19.19. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44. The company has a market capitalization of $713.27 million, a PE ratio of -11.53 and a beta of 0.99.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The firm had revenue of $26.49 million during the quarter, compared to analyst estimates of $26.09 million. Equities research analysts expect that CeriBell, Inc. will post -1.69 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on CBLL. BTIG Research reiterated a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a report on Wednesday, January 28th. Canaccord Genuity Group dropped their price target on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Finally, Weiss Ratings cut shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, CeriBell presently has an average rating of “Moderate Buy” and a consensus target price of $22.20.

Institutional Investors Weigh In On CeriBell

Large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its stake in shares of CeriBell by 6,424.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock worth $7,117,000 after acquiring an additional 374,179 shares in the last quarter. Rhumbline Advisers boosted its position in CeriBell by 109.9% during the second quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock worth $614,000 after acquiring an additional 17,177 shares during the last quarter. New York State Common Retirement Fund increased its holdings in shares of CeriBell by 148.6% in the second quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock valued at $163,000 after purchasing an additional 5,200 shares during the last quarter. Quantbot Technologies LP boosted its position in shares of CeriBell by 70.3% during the 2nd quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock valued at $290,000 after acquiring an additional 6,401 shares during the last quarter. Finally, Invesco Ltd. purchased a new stake in shares of CeriBell in the 2nd quarter valued at approximately $197,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.